Grace Therapeutics, Inc.
Grace Therapeutics (GRCE) shares rose 1.7% in pre-market trading as investors await an FDA decision on April 23 for its brain bleed drug GTx-104. The drug showed a 19% reduction in hypotension in trials and has Orphan Drug Designation, which could grant market exclusivity. Retail sentiment on Stocktwits turned neutral from bearish, with high message volumes.
Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104
Grace Therapeutics (GRCE) reported a Q1 2027 net loss of $15.8M for the quarter ended June 30, 2026, versus a $3.4M loss a year earlier. Diluted EPS was $(0.91) versus $(0.21). Revenue was not reported. The company received an FDA Complete Response Letter for GTx-104, citing CMC and nonclinical items, and is pursuing an NDA resubmission.
Over the past 7 days, alphai's AI scored 1 news story mentioning GRCE (Grace Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent GRCE coverage spans regulation, earnings and corporate actions.
In the last 30 days, GRCE insiders filed 1 SEC Form 4 transaction — 1 purchase ($24K) and no sales. The most active reporter was Opaleye Management Inc. with 1 filing.
Approval could trigger a sharp rally; denial would likely cause a sell‑off.
Near-term focus is FDA resubmission readiness and cash runway into 2028, with dilution risk from the $10M financing.
FDA CRL plus pipeline funding shift increases regulatory and execution risk for GTx-104, partially offset by Phase 3 STRIVE-ON success.
The impairment reduces near-term reported profitability and can imply program-level write-downs, while the runway extension to 2028 reduces immediate liquidity risk.
The filing signals a capital raise via a private placement, which can pressure dilution expectations and near-term liquidity/financing risk.
alphai scores every news story that mentions GRCE with an AI model for sentiment and relevance, and aggregates insider trades from Grace Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Grace Therapeutics (GRCE) shares rose 1.7% in pre-market trading as investors await an FDA decision on April 23 for its brain bleed drug GTx-104. The drug showed a 19% reduction in hypotension in trials and has Orphan Drug Designation, which could grant market exclusivity. Retail sentiment on Stocktwits turned neutral from bearish, with high message volumes.
1 min readGrace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104
6 min readGrace Therapeutics (GRCE) reported a Q1 2027 net loss of $15.8M for the quarter ended June 30, 2026, versus a $3.4M loss a year earlier. Diluted EPS was $(0.91) versus $(0.21). Revenue was not reported. The company received an FDA Complete Response Letter for GTx-104, citing CMC and nonclinical items, and is pursuing an NDA resubmission.
1 min readGrace Therapeutics, Inc. (GRCE) filed a Form 10-Q for the quarter ended June 30, 2026. The filing states it recorded a $13.5M R&D impairment and extended its cash runway to 2028. The report also lists GRCE’s Nasdaq ticker (GRCE) and share count outstanding as of Aug. 11, 2026.
4 min readGrace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Grace Therapeutics Announces $10 Million Private Placement Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028 PRINCETON, N.J., August 4, 2026 – Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Comp
4 min readGrace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr
4 min read
